|
|
 |
|
Viewing report
|
|
|
|
Pipeline Insight: Depression - Novel therapies key to market penetration
Datamonitor, Sep 2003, Pages: 168
Introduction:
With the global antidepressant market valued at $16.6 billion in 2002, drugs for the treatment of depression have historically provided huge returns on investment. However, several of the leading brands are expecting patent expiries over the next five years. New strategies are needed to prevent a decline in the antidepressant market.
Scope:
- Detailed coverage of the patient potential, unmet needs, and clinical trial design of antidepressants across the seven major markets
- Overview of the drugs in preregistration, Phase III, II, I and preclinical development, with in-depth profiles of Organon and Dov Pharmaceutical
- Profiles of compounds undergoing development for depression, with sales forecasts to 2011, and insight into innovative early stage products
- Evaluation of key clinical trials in the treatment of depression, with revenue forecasts to 2011
Report Highlights:
Duloxetine, Eli Lilly’s follow-up compound to Prozac, is set to become the next drug to enter the antidepressant market. However, convincing physicians that it is superior to Wyeth’s Effexor may prove challenging. Lilly needs to position duloxetine as an alternative first-line therapy to selective serotonin reuptake inhibitors (Ssris).
Merck’s NK1 receptor antagonist, aprepitant, is expected to be the first drug from another completely new class of antidepressants to hit the market. Its launch in 2006 will precipitate an influx of similar compounds to the market, presenting a major threat to the leading position of first-line therapy Ssris.
Reasons to Purchase:
- Understand the depression market unmet needs to devise market-penetrating strategies
- Analyze the competitive environment at the time of product launch
- Identify in-licensing and co-promotional opportunities
Customers who bought this item also bought
Drugs of Tomorrow 2002: Depression - A pipeline driven by side effect profile
Pipeline Insight: Depression - Novel Drugs to Grow Third-line Market
Drugs of Tomorrow 2001: Depression - A Future Away From Serotonin?
Br. Holdings Corporation
Br Malls Participacoes Sa
Pipeline Insight: Antipsychotics - Novel Antipsychotics Driving Market Evolution
Drugs of Tomorrow 2001: Stable Angina - An Unsatisfactory R&D Pipeline Facing Chronic Unmet Needs
The World Market for Butadiene Rubber (BR): A 2009 Global Trade Perspective
The 2009 Import and Export Market for Butadiene Rubber (BR) in Iran
The 2009 Import and Export Market for Butadiene Rubber (BR) in Belarus
The 2009 Import and Export Market for Butadiene Rubber (BR) in Bulgaria
The 2009 Import and Export Market for Butadiene Rubber (BR) in Colombia
|
|
|
|
